Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher

Researchers

B Douglas Smith, M.D.

Photo of Dr. B Douglas Smith, M.D.
  • Co-director, Clinical Research Operations for the Division of Hematologic Malignancies
  • Professor of Oncology
Male

Expertise

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders ...read more

Research Interests

Drug Development for Patients with Acute and Chronic Leukemias

Request an Appointment

Insurance Information

Maryland

410-955-8964

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-614-5068 | Fax: 410-614-7437

The Bunting Blaustein Cancer Research Building

1650 Orleans Street
Baltimore, MD 21287 map

Background

Dr. B. Douglas Smith is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders and he is recognized nationally as an expert in the care of patients with these disorders and as a leader in novel therapeutics for these conditions.  Dr. Smith serves as the Co-Director of Clinical Research Operations for the Division of Hematologic Malignancies and helps to manage the Division’s clinical research trials.

Dr. Smith received his undergraduate degree in Biology from Lafayette College (Easton, PA), earned his M.D. at the Medical College of Pennsylvania (Philadelphia, PA), completed his Residency at Strong Memorial Hospital of the University of Rochester (Rochester, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Smith joined the Johns Hopkins faculty in 1998 at the completion of his training.

His main research interests include drug development for patients with AML, CML, and MDS and he serves as Co-Investigator for the Oncology Center’s UM1 (early phase drug development) Grant. The Leukemia Program’s clinical trials portfolio has included trials for each of the 8 newly FDA-approved drugs for acute leukemia in the past 2 years.  

Dr. Smith has a passion for teaching trainees and has served on the Fellowship Executive Committee since 2010 focusing on the program’s educational platforms. He has won numerous teaching awards in both the Department of Oncology and the Department of Medicine multiple times, and he has a track record of mentoring fellows pursuing clinical-translational research and clinician-educator pathways.  In 2020, Dr. Smith was awarded membership in the prestigious Miller Coulson Academy for Excellence in Clinical Care.

He is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research. He has served on the National Comprehensive Cancer Network guideline panel for CML since 2001 and previously served on the AML panel from 2001-2015. Dr. Smith has extensive experience in the regulatory aspects of drug development and he currently serves as the Chair of the Johns Hopkins Institutional Review Board #2.

...read more

Titles

  • Co-director, Clinical Research Operations for the Division of Hematologic Malignancies
  • Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD, Drexel University College of Medicine (1991)

Residencies

  • Strong Memorial Hospital of the University of Rochester / Internal Medicine (1995)

Fellowships

  • Johns Hopkins University School of Medicine / Medical Oncology (1998)

Research & Publications

Research Summary

Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them into biology-based treatment approaches for patients with AML, CML, and MDS.  He has helped to translate numerous new therapies into the clinic, including differentiation-based strategies; targeted, small-molecule inhibitors of signal transduction pathways (FLT3-ITD, raf kinase, ras kinase, and bcr-abl); agents that alter cell cycle and DNA-damage repair; and immunomodulatory approaches. Dr. Smith’s work integrates biologic correlative studies and biomarkers along with molecular monitoring for minimal residual disease to help determine the ultimate impact of the novel treatments.

Clinical Trial Keywords

AMl, CML, MDS, Acute and Chronic Leukemias, Myeloid Disorders and Bone Marrow Malignancies

Selected Publications

View all on Pubmed

Cortes JE, Smith BD, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Shaik MN, Laird AD, O'Connell A, Chan G, Schroeder MA. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018; 93(11):1301-1310. doi: 10.1002/ajh.25238. PMID: 30074259.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AM, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD. A mulit-center Phase 1 trial of ipilimumab in Patients with myelodysplastic syndromes following hypomethylating agent failure. Clin Cancer Res. 2018;24(15):3519-3527. Epub 2018. PMID: 29716921

Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, Murgo A, Rudek MA, Matsui WH. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Research. 2011;35(1):87-94. PMCID: PMC3033102

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedryzycki B, Harding TC, Tu, GH, Jones RJ, Hege K, Levitsky HI. K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. Clin Cancer Res. 2010;16(1):338-47. PMCID: PMC2804932

Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294-301. PMCID: PMC3069671

Activities & Honors

Honors

  • Osler Housestaff Teaching Award, Department of Medicine, 2006
  • Osler Housestaff Teaching Award, Department of Medicine, 2009
  • Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center, 2010
  • NCI/NIH Cancer Clinical Investigator Team Leadership Award, 2012
  • Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center, 2015
  • Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center, 2019
  • Membership, Miller Coulson Academy for Excellence in Clinical Care, 2020

Memberships

  • American Society of Hematology, 1996
  • American Society of Clinical Oncology, 1996
  • American Association for Cancer Research, 1998

Professional Activities

  • Co-Director, Tumor Cell Procurement Bank, 2001
  • Advisory Board, Hackerman-Patz Patient and Family Pavilion, 2010
  • Medical Advisory Board, Hemedicus – A Continuing Medical Education Company, 2013
  • Medical Advisory Board, AA-MDS International Foundation, 2013
  • Chief Scientific Officer, AML-combine, a non-profit developing novel therapies for AML, 2016
  • Chair, Johns Hopkins Medicine Institutional Review Board 2, 2018
  • Co-Director, Clinical Research Operations, Division of Hematologic Malignancies, 2018

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button